Equities researchers at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a research note issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
BLPH stock opened at $1.09 on Monday. The company has a market cap of $10.40 million, a P/E ratio of -0.55 and a beta of 0.01. Bellerophon Therapeutics has a 1 year low of $0.67 and a 1 year high of $3.72. The stock’s fifty day moving average price is $1.12 and its 200-day moving average price is $1.17.
Hedge Funds Weigh In On Bellerophon Therapeutics
A hedge fund recently raised its stake in Bellerophon Therapeutics stock. Renaissance Technologies LLC raised its holdings in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) by 13.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 209,399 shares of the biotechnology company’s stock after acquiring an additional 24,100 shares during the quarter. Renaissance Technologies LLC owned approximately 2.19% of Bellerophon Therapeutics worth $258,000 as of its most recent SEC filing. 11.92% of the stock is currently owned by institutional investors.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.